Amgen terminates TScan Therapeutics collaboration, removing $500 million in milestone potential for TCRX
$TCRX is in focus after Amgen notified TScan Therapeutics on August 12, 2026, that it is terminating, in full, the research collaboration the two companies have operated since May 2023. The deal had carried…
Key takeaways
- Amgen notified TScan Therapeutics on August 12, 2026, that it is terminating in full the research collaboration the companies had run since May 2023.
- The termination removes over $500 million in aggregate success-based milestone potential, which TScan does not expect to collect.
- The $30 million upfront payment TScan received in 2023 is non-refundable and stays with the company.
- The collaboration used TScan's target discovery platform to identify antigens recognized by T-cells in Crohn's disease patients, with Amgen holding an exclusive worldwide license.
- The termination becomes effective November 10, 2026, and TScan must wind down its research activities by that date.
$TCRX is in focus after Amgen notified TScan Therapeutics on August 12, 2026, that it is terminating, in full, the research collaboration the two companies have operated since May 2023. The deal had carried success-based milestones of over $500 million in the aggregate. TScan said in the filing it does not expect to collect those payments once the agreement ends.
Amgen exercised its contractual right to exit on ninety days' notice, with no early-termination penalty owed. The collaboration put TScan's proprietary target discovery platform to work identifying antigens recognized by T-cells in Crohn's disease patients. Amgen held an exclusive, worldwide, sublicensable license to develop and commercialize any product candidates created during the collaboration.
The $30 million upfront payment TScan received from Amgen in 2023 is non-refundable and stays with the company. That number is settled. The milestone stack and tiered single-digit royalties on net sales are now contingent on whether Amgen, its affiliates, or sublicensees choose to continue exploiting candidates from the collaboration. The 8-K acknowledges those obligations survive termination if Amgen proceeds, but TScan does not expect them to materialize.
Between now and November 10, TScan must wind down its activities under the then-current research plan with commercially reasonable efforts. What the platform looks like after that date, and how TScan recaptures the commercial runway Amgen is walking away from, are the questions the filing does not answer. The 8-K, dated August 18 and signed by Chief Executive Officer Gavin MacBeath, Ph.D., is silent on replacement programs or new partners.
The setup from here is thin. A $500-million-plus milestone stack is contingent value, but it is the kind of number that frames how analysts model a biotech's peak revenue potential. Its removal means the Crohn's disease program no longer sits on TScan's ledger as near-term optionality. The platform remains, but it needs a new taker.
What to watch: any disclosure from Amgen indicating it intends to continue development of candidates from the collaboration, which would keep the milestone and royalty provisions alive on their original terms. The termination becomes effective November 10, 2026.